KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Divestments (2017 - 2021)

Abbott Laboratories (ABT) has disclosed Divestments for 5 consecutive years, with $86.0 million as the latest value for Q3 2021.

  • Quarterly Divestments changed N/A to $86.0 million in Q3 2021 from the year-ago period, while the trailing twelve-month figure was $86.0 million through Dec 2022, down 10.42% year-over-year, with the annual reading at $1.0 million for FY2024, 97.5% down from the prior year.
  • Divestments hit $86.0 million in Q3 2021 for Abbott Laboratories, up from $10.0 million in the prior quarter.
  • In the past five years, Divestments ranged from a high of $1.7 billion in Q1 2017 to a low of -$29.0 million in Q3 2017.
  • Historically, Divestments has averaged $391.8 million across 3 years, with a median of $48.0 million in 2020.
  • Biggest YoY gain for Divestments was 6640.0% in 2017; the steepest drop was 6640.0% in 2017.
  • Year by year, Divestments stood at $600.0 million in 2017, then tumbled by 98.33% to $10.0 million in 2020, then skyrocketed by 760.0% to $86.0 million in 2021.
  • Business Quant data shows Divestments for ABT at $86.0 million in Q3 2021, $10.0 million in Q4 2020, and $600.0 million in Q4 2017.